Treatment of colorectal cancer (CRC)—the third leading cause of cancer-related death in the United States—remains challenging even today. But according to leading oncologists in the field, ...

Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA ...

Universal mismatch repair (MMR) deficiency testing is widely recommended in patients with colorectal cancer (CRC) and others with a family history of MMR deficiency to identify Lynch syndrome, a ...

Artificial intelligence (AI) –powered spatial analysis of macrophages in tumor microenvironment and its association with interferon-gamma (IFNG) signature and immune phenotype (IP) in pan-cancer ...

Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...

Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by hypermutation leading to abundant neoantigens that activate an antitumor immune response in the tumor ...

Mismatch repair-deficient (dMMR) colorectal cancer (CRC) is associated with a conspicuous local immune infiltrate; however, its relationship with systemic inflammatory responses remains to be ...

Keytruda received FDA breakthrough therapy designation for MSI-H mCRC, based on promising phase 2 study results in MMR-deficient patients. The study showed a 62% objective response rate in ...

A role of mismatch repair (MMR) in modulating colorectal cancer (CRC) was assessed by genotyping single nucleotide polymorphisms in five MMR genes in hospital-based case- control study. The TAG ...